Related Experiment Videos

Cardiac allograft vasculopathy: current concepts

H O Ventura1, F W Smart, D D Stapleton

  • 1Ochsner Medical Institutions, New Orleans, LA 70121.

Insights

Cardiac allograft vasculopathy, a major cause of late death in heart transplant patients, is a unique intimal hyperplastic process. Retransplantation is the only current definitive therapy, but results are fair.

Area of Science:

  • Cardiology
  • Transplantation Immunology

Background:

  • Cardiac allograft vasculopathy (CAV) is the leading cause of late mortality in heart transplant recipients, affecting 15-20% of patients.
  • CAV is distinct from traditional atherosclerosis, characterized by concentric intimal hyperplasia, intact internal elastic lamina, and rare calcification.

Purpose of the Study:

  • To describe the characteristics, potential causes, diagnostic methods, and treatment of cardiac allograft vasculopathy.

Main Methods:

  • Review of existing literature on cardiac allograft vasculopathy.
  • Comparison of diagnostic modalities including coronary angiography, intravascular ultrasound, and coronary angioscopy.
  • Evaluation of retransplantation as a therapeutic option.

Main Results:

  • CAV typically affects the distal coronary arteries, leading to rapid occlusion.
  • Immunologic and non-immunologic endothelial damage may drive the myointimal proliferation seen in CAV.
  • Intravascular ultrasound and coronary angioscopy show higher sensitivity for CAV detection than coronary angiography.

Conclusions:

  • Cardiac allograft vasculopathy presents unique pathological features compared to atherosclerosis.
  • While retransplantation is the only definitive treatment, its success rates are currently limited.

Related Concept Videos